Trevi Therapeutics Announces Appointment of James V. Cassella, Ph.D.
Trevi Therapeutics(TRVI) Prnewswire·2024-09-30 21:30NEW HAVEN, Conn., Sept. 30, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinicalstage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced the appointment of James V. Cassella, Ph.D., as Chief Development Officer (CDO). "I am delighted to welcome Jim, who has been a member of our Board of Directors for the past four years, ...